GOVERNMENT OF INDIA
MINISTRY OF HEALTH AND FAMILY WELFARE
DEPARTMENT OF HEALTH AND FAMILY WELFARE

LOK SABHA
UNSTARRED QUESTION NO. †2502
TO BE ANSWERED ON 13TH FEBRUARY, 2026

USE OF GLP-1 MEDICATIONS

†2502. SHRI OMPRAKASH BHUPALSINH *ALIAS* PAVAN RAJENIMBALKAR:

Will the **Minister of HEALTH AND FAMILY WELFARE** be pleased to state:

(a) whether the Government has taken cognizance of the increasing use and market expansion of weight loss drugs, specifically GLP-1 receptor agonists in the country and if so, the details thereof;

(b) whether these drugs are approved for use in the country for obesity management along with the regulatory framework governing their prescription, sale and monitoring in this regard and if so, the details thereof;

(c) whether the Government has conducted any assessment of the health risks, side effects and long-term safety concerns associated with the non-therapeutic or aesthetic use of these drugs and if so, the details thereof; and

(d) whether any guidelines have been issued by the Government to prevent misuse, excessive prescription or self-medication of these drugs, particularly through online platforms and if so, the details thereof?

ANSWER
THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE
(SMT. ANUPRIYA PATEL)

(a) to (d): Central Drugs Standard Control Organization (CDSCO) has approved the following three drugs for obesity/weight management in the country

(i) Orlistat

(ii) Tirzepatide

(iii) Semaglutide

These drugs are required to be sold in retail on the prescription of endocrinologist or Internal Medicine/ specialists only as per the conditions of approval issued by CDSCO. All drugs should be used/consumed in accordance with recommendations for use.

Regulatory control over the sale and distribution of drugs is exercised through a system of licensing and inspection by State Licensing Authorities (SLAs) appointed by State Government. SLAs are empowered to take action in case of violation of regulatory provisions of Drugs and Cosmetics Act, 1940 & Rules 1945.

The Indian Pharmacopoeia Commission (IPC) as National Coordination Centre (NCC) for Pharmacovigilance Programme of India (PvPI) collates and analyses, Individual Case Safety Reports (ICSRs) related to adverse drug reactions.

****